EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry

Diego F Wyszynski, Lydia Demetriou, Cheryl Renz, Shirin Aliabadi, Dragutin Rafailovic, Lee P Shulman, Myriam Drysdale, Keele E Wurst

Drug Safety · 2024

DOI: 10.1007/s40264-024-01439-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Safety, 2024. Verfasst von Diego F Wyszynski und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pregistry, London, UK. diegow@pregistry.com. Hauptthemen laut MEDLINE: Registries, COVID-19, Pregnancy Complications, Infectious, COVID-19 Drug Treatment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK and Vir Biotechnology, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Available data regarding the safety and efficacy of sotrovimab in pregnant patients remain limited due to their exclusion from clinical trials. METHODS: The COVID-19 International Drug Pregnancy Registry (COVID-PR) was established to gather comprehensive safety data from pregnant women who have received monoclonal antibody (mAb) or antiviral treatments for mild, moderate, or severe coronavirus disease 2019 (COVID-19) during pregnancy. Participants actively contributed self-reported data concerning their COVID-19 symptoms, in addition to sociodemographic and health-related characteristics. Obstetric, neonatal, and infant outcomes were also documented, with follow-up extending up to 12 months after childbirth. RESULTS: As of 30 November 2023, sotrovimab was administered to 39 participants enrolled in the COVID-PR. At the time of this report, 26 participants had given birth, with nine deliveries performed via cesarean section. The infants' birthweight ranged from 2381 g to 4762 g, with a mean of 3439.91 g. Twenty-five infants were born at ≥37 weeks. A total of 31 adverse events (AEs) were reported by 12 participants. The most frequently reported AE was gestational hypertension, observed in three participants. COVID-19 re-infection, fatigue, gestational diabetes, headache, and morning sickness were each reported by two participants. Of the reported AEs, eight (in five participants) were classified as serious, including four AEs (prolonged labor, pre-eclampsia, polyhydramnios, premature labor) that affected pregnancy. Seven of these eight serious AEs (SAEs) were found to be unrelated to sotrovimab, with one event (urinary retention) not assessable. A total of 44 AEs were reported in 19 delivered infants or in utero fetuses. The most common were COVID-19 (n = 6 events), ear infection (n = 5 events), neonatal dyspnea (n = 3 events), and respiratory syncytial virus infection (n = 3 events). Sixteen AEs (in 11 infants/fetuses) were classified as serious, including one report each of fetal cardiac disorder, congenital ankyloglossia, persistent right umbilical vein, and congenital hydronephrosis; the latter was considered a major congenital malformation. For all assessable SAEs, causality of sotrovimab treatment was ruled out based on lack of a temporal relationship alone or in combination with absence of a plausible mechanism. CONCLUSION: A sizable proportion of sotrovimab-treated participants in the COVID-PR had underlying medical conditions associated with an increased risk of severe COVID-19. None of the assessable SAEs were considered to be related to sotrovimab treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RegistriesCOVID-19Pregnancy Complications, InfectiousCOVID-19 Drug TreatmentHumansPregnancyFemaleAdultInfant, NewbornAntiviral AgentsPregnancy OutcomeYoung AdultSARS-CoV-2Antibodies, Monoclonal

Substanzen

Antiviral AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Pregistry, London, UK. diegow@pregistry.com.
  • GSK, Stevenage, UK.
  • Pregistry, Los Angeles, CA, USA.
  • Division of Clinical Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • GSK, Brentford, UK.
  • GSK, Research Triangle Park, Durham, NC, USA.

Förderung

  • GSK and Vir Biotechnology, Inc.

Zitieren

APA

Wyszynski, D. F., Demetriou, L., Renz, C., Aliabadi, S., Rafailovic, D., Shulman, L. P., Drysdale, M., & Wurst, K. E. (2024). Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry. Drug Safety. https://doi.org/10.1007/s40264-024-01439-z

Vancouver

Wyszynski DF, Demetriou L, Renz C, Aliabadi S, Rafailovic D, Shulman LP, et al. Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry. Drug Safety. 2024. doi:10.1007/s40264-024-01439-z

BibTeX
@article{Wyszynski2024,
  author = {Wyszynski, Diego F and Demetriou, Lydia and Renz, Cheryl and Aliabadi, Shirin and Rafailovic, Dragutin and Shulman, Lee P and Drysdale, Myriam and Wurst, Keele E},
  title = {Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry},
  journal = {Drug Safety},
  year = {2024},
  doi = {10.1007/s40264-024-01439-z}
}
Kostenlos starten →